 Protalix concluded its Type A meeting with the US Food and Drug Administration FDA, providing a way forward with its lead indication PRX-102. Protalix published top line results of the interim analysis of its BALANCE trial on June 2, 2021 and announced completion of the treatment period on October 15, 2021. 